Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cannabis Bioscience International Holdings (CBIH) EBIT Margin (2022 - 2026)

Cannabis Bioscience International Holdings filings provide 5 years of EBIT Margin readings, the most recent being 832.3% for Q1 2026.

  • On a quarterly basis, EBIT Margin rose 3324.0% to 832.3% in Q1 2026 year-over-year; TTM through Feb 2026 was 322.6%, a 23069.0% decrease, with the full-year FY2025 number at 139.05%, up 5631.0% from a year prior.
  • EBIT Margin reached 832.3% in Q1 2026 per CBIH's latest filing, down from 180.0% in the prior quarter.
  • The five-year high for EBIT Margin was 39.06% in Q2 2024, with the low at 865.54% in Q1 2025.
  • A 5-year average of 353.4% and a median of 275.89% in 2023 define the central range for EBIT Margin.
  • Year-over-year, EBIT Margin surged 55324bps in 2024 and then crashed -42619bps in 2025.
  • Year by year, EBIT Margin stood at 222.34% in 2022, then surged by 33bps to 148.26% in 2023, then skyrocketed by 46bps to 80.31% in 2024, then tumbled by -124bps to 180.0% in 2025, then plummeted by -362bps to 832.3% in 2026.
  • Per Business Quant, the three most recent readings for CBIH's EBIT Margin are 832.3% (Q1 2026), 180.0% (Q4 2025), and 309.02% (Q3 2025).